Gastric Residence Time Research Articles

DESIGN, OPTIMIZATION, AND EVALUATION OF RAFT FORMING GASTRO RETENTIVE DRUG DELIVERY SYSTEM OF LAFUTIDINE USINGBOX–BEHNKEN DESIGN

Objective: The current research was aimed to formulate and evaluate raft forming gastro retentive floating drug delivery systems of Lafutidine for improving gastric residence time and sustained drug release for an extended time. Methods: Using Box–Behnken experimental design 17 formulations of lafutidine GRDDS were designed and evaluated for various parameters like physical appearance, pH, In vitro gelling study, in vitro buoyancy study, measurement of viscosity, density measurement, gel strength, drug content, acid neutralization capacity, the profile of neutralization, in vitro dissolution, release kinetic and stability studies. Results: All the evaluations were performed and observed that the values were within range, and the buoyancy lag time ranged within 14.76 to 25.84 sec and the formulations remained buoyant for more than 8h with the gelling time of 12h, the drug content was ranging from 98.96 to 99.55 %, and in vitro release was 86.86 to 99.34% by the end of 12h. The release kinetics followed zero-order with Higuchi’s model that indicating that drug release was found to be followed by the matrix diffusion process. Conclusion: Out of all formulations F3 was the optimized formulation and it was further characterized for FTIR, DSC, and stability studies, which exposed that there were no interactions amongst drug and excipients and no major change in the formulation and found to be stable.

Factorial design approach to fabricate and optimize floating tablets based on combination of natural polymer and rice bran wax

BackgroundThe aim of the present research work was to fabricate a novel gastroretentive drug delivery system in the form of tablets using a combination of natural polymer and rice bran wax with an intention to control drug delivery and to enhance the gastric residence time of the model drug Famotidine in the gastrointestinal tract.ResultsThe results of the preliminary trial batches prepared by using the hot melt granulation technique resulting in six different formulations showed good physicochemical characteristics and tablets conformed to the Pharmacopoeial specifications. Gastroretentive tablets containing natural polymer showed prolonged drug release comparable to Methocel. The optimized formulation (C3) using 32 factorial design showed FLT 27 ± 2.47 s, SI 92.68 ± 1.36% and % CDR 98.89 ± 0.39% at 12 h. The stability studies indicated the stability of the formulation during storage.ConclusionsIt was concluded that the release profile fitted best to zero-order equation with non-Fickian diffusion mechanism of drug release which demonstrates swelling-controlled drug release mechanism. Thus, the formulated tablets have the potential for improved release and gastroretentive properties.Graphical

Formulation and evaluation of Lamivudinefloating tablets usingCarbopol & Eudragit S 100

Lamivudinecomes underclass II drugs according to BCS classification. It is poorly water-soluble drug. It has maximum solubility in pH 1.2 and therefore it will be beneficial to retain the drug in stomach for longer period of time for better absorption. Hence, it was found necessary to develop a gastric retentive dosage form containing Lamivudinein order to increase the gastric residence time to enhance its absorption and they’re by its oral bioavailability. Also, the slow release of the drug in stomach may avoid the stomach pain associated with immediate release of the drug. The ultimate aim was to design, develop and optimize the floating tablets containing Lamivudinein order to increase its gastric retention time for enhancing absorption in stomach as well as to produce a controlled release of the drug for a longer time using polymers such as Carbopol, and EudragitS100.

Development and Characterization of Repaglinide Loaded Floating Microparticles

Sustained release drug delivery has been successfully achieved using microparticles made from natural or synthetic polymers. The aim of this study is to develop and test floating microparticles of Repaglinide in order to improve drug bioavailability by extending gastric residence time. Repaglinide, an oral hypoglycemic, is a lipophilic drug that is rapidly absorbed from the stomach and eliminated with a half-life of just 1 h, so suitable to be formulated as floating drug delivery system for sustained release.Repaglinide floating microparticles were developed using an ionotropic gelation method that included calcium chloride as a cross-linking agent, sodium alginate, and different concentrations of hydroxypropyl methylcellulose (HPMC), ethyl cellulose (EC), and sodium bicarbonate (NaHCO3). A three factor, three-level Box-Behnken design was used to study the effect of independent variables on dependent variables. In the formulation of microparticles, the amount of hydroxypropyl methylcellulose (X1), ethyl cellulose (X2), and sodium bicarbonate (X3) were three independent variables, while percentage buoyancy (Y1) and percentage drug release at 10 h (Y2) were dependent variables. Micromeritic properties, percent yield, percent drug entrapment performance, surface morphology, percent buoyancy, in-vitro drug release, and drug excipient compatibility were all assessed in the formulations.FTIR studies revealed no interaction between the drug and the excipients.SEM for surface morphology studies revealed that their surface is spherical and smooth. The mean particle size of formulations was found to be between 415- 689 µm, the drug entrapment efficiency was found to be between 44.65% - 76.55% and percent buoyancy was noted to be between 63%- 78.33%. The results revealed that entrapment efficiency increased as polymer concentration was increased. The cumulative percent drug release after 10 h was noted to be between 76.87- 88.12%. Percent drug release decreased as polymers concentration was increased. The buoyancy was increased with increasing concentration of sodium bicarbonate. The developed microparticles could successfully retard the release of the drug.

Formulation and in-vitro Evaluation of Carvedilol Gastroretentive Capsule as (Superporous Hydrogel)

The preferred route of drug administration is the oral route, but drugs with narrow absorption window in the gastrointestinal tract are still challenging. The ability to extend and monitor the gastric emptying time is a valuable tool for processes remaining in the stomach longer than other traditional dosage forms.
 The purpose of this study was to formulate and evaluate gastroretentive superporous hydrogel (SPH) of carvedilol with view to improve its solubility and increase gastric residence time in order to get sustained release formulas via utilization of various kinds and concentrations of hydrophilic polymers then after, incorporate the best prepared formula into capsules.
 Sixteenth formulae of SPH hybrid were prepared by gas blowing technique from the following materials; monomers (Poly vinyl alcohol, and Acrylamide), cross-linkers (Methylene bisacrylamide, and glutaraldehyde), hybrid agent (Chitosan), foaming agent (NaHCO3) and foam stabilizer (Tween 80). Different amounts or concentrations of these materials were utilized to investigate their effect on SPH properties (density, porosity, floating, drug content, drug release, swelling time, and swelling ratio). The soaking procedure was utilized for loading of carvedilol into SPH hybrid (6.25mg/2.5g SPH).
 After analysis the results statistically and application the similarity factor (f2) equation, formula F8 was selected as the best formula and incorporated into capsules.
 The drug release data were applied to different mathematical kinetics and the results were shown to be fitted to Higuchi model and the release mechanism was (non fickian) diffusion.
 The overall results suggested that the proposed SPH hybrid drug delivery system is encouraging for carvedilol specific delivery to the stomach.

Development and characterization of effervescent floating tablet of famotidine for treatment of peptic ulcer

Floating drug delivery systems (FDDS) are utilized to target drug discharge in the stomach or to the upper parts of intestine. Famotidine has been the most extensively used drug for the management of peptic ulcer for various decades. The current study concerns the development and evaluation of floating tablets of famotidine which, after oral administration, are planned to extend the gastric residence time, enhance drug bioavailability and aim the gastric ulcer. A FDDS was expanded using gas-forming agents, like sodium bicarbonate, citric acid and hydrocolloids, like hydroxypropyl methylcellulose (HPMC) and carbopol 934P. The prepared tablets were evaluated in terms of their pre-compression parameters, physical characteristics, buoyancy, buoyancy lag-time, in vitro release, and swelling index. The formulations were optimized for the different viscosity grades of HPMC, carbopol 934P and its concentrations and combinations. The consequences of the in vitro release studies demonstrated that the optimized formulation (F6) could sustain drug release (98%) for 24 h and remain buoyant for 24 hr. Optimized formulation (F6) showed no considerable change in physical appearance, drug content, total buoyancy time or in vitro dissolution study after storage at 40°C/75% RH for 3 months. Lastly the tablet formulations establish to be economical and may conquer the draw backs associated with the drug during its absorption.
 Keywords: Famotidine, Floating drug delivery system, Hydrocolloids, Gastric residence time.

Formulation And Evaluation Of Floating Microspheres Of Cefdinir

Various approaches have been used to retain the dosage form in the stomach as a way ofincreasing the gastric residence time (GRT), including floatation systems; high-density systems; mucoadhesive systems; magnetic systems; unfoldable, extendible, or swellable systems; andsuperporous hydrogel systems. The aim of this study was to prepare and evaluate floatingmicrospheres of cefdinir for the prolongation of gastric residence time. Themicrospheres were prepared byCapillary Extrusion method.A full factorial design was applied to optimize the formulation. The optimum batch of microsphere exhibited smooth surfaces with good flow and packing properties, prolonged sustained drug release, remained buoyant for more than 12 hrs, high entrapment efficiency upto68%.Scanning electron microscopy confirmed the hollown structure with particle size in the order of190 μm. The studies revealed that increase in concentration of gum Karaya increased the drug release from the floating microspheres.

FORMULATION AND CHARACTERIZATION OF CLARITHROMYCIN FLOATING TABLETS BY USING VARIOUS POLYMERS

The present study outlines a systematic approach for designing and development of Clarithromycin floating tablets to enhance the bioavailability and therapeutic efficacy of the drug. Floating tablets of Clarithromycin have shown sustained release there by proper duration of action at a particular site and are designed to prolong the gastric residence time after oral administration. Different formulations were formulated by using direct compression technique. A floating drug delivery system (FDDS) was developed by using sodium bicarbonate as gas-forming agent and Chitosan, HPMC K4M and Ethyl cellulose as polymers. The preformulation parameters like Organoleptic properties, angle of repose, bulk density, tapped density, Hausners ratio, carrs index and compressibility index of pure drug was evaluated and complied with the pharmacopoeial specifications. FTIR studies showed there was no interaction between drug and polymer. The prepared tablets were evaluated in terms of their physical characteristics, post compression parameters in vitro release and buoyancy lag time the results of the in vitro release studies showed that the optimized formulation (C7) could sustain drug release for 12 hrs by using Ethyl cellulose in the concentration of 50 mg. The in vitro drug release followed Kors Mayer peppas release. Results revealed that the floating formulation of the Clarithromycin is the best formulation to obtain better therapeutic effect and Ethyl cellulose at a concentration of 50mg up to some extent it increases the Bioavailability of the drug to retain the dosage form on the desired site for effective period of the time.

Floating Microsphere of Curcumin as Targeted Gastro-retentive Drug Delivery System

Microspheres carrier system made from natural or synthetic polymers used in sustained release drug delivery system. The present study involves formulation and evaluation of floating microspheres of Curcumin for improving the drug bioavailability by prolongation gastric residence time. Curcumin, natural hypoglycemic agent is a lipophilic drug, absorbed poorly from the stomach, quickly eliminated and having short half-life so suitable to formulate floating drug delivery system for sustained release. Floating microspheres of curcumin were formulated by solvent evaporation technique using ethanol and dichloromethane (1:1) as organic solvent and incorporating various synthetic polymers as coating polymer, sustain release polymers and floating agent. The final formulation were evaluated various parameters such as compatibility studies, micrometric properties, In-vitro drug release and % buoyancy. FTIR studies showed that there were no interaction between drug and excipients. The surface morphology studies by SEM confirmed their spherical and smooth surface. The mean particles size were found to be 416-618µm, practical yield of microspheres was in the range of 60.21±0.052% - 80.87±0.043%, drug entrapment efficiency 47.4±0.065% - 77.9±0.036% and % buoyancy 62,24±0.161% - 88.63±0.413%. Result show that entraptmency increased as polymer (Eudragit RS100) conc. Increased. The drug release after 12 hrs. was 72.13% - 87.13% and it decrease as a polymer (HPMC, EC) concentration was decrease.

Design, Development, Formulation, and Evaluation of Gastro retentive Floating Tablet for Anti-diabetic Agent

The main aim of the research was to persist the gastric residence time of vildagliptin by designing its gastro-retentive tablet as well as to study the effect of different polymers on its release rate using 23 randomized full factorial designs. Tablets are manufactured by direct compression method. Hydroxypropyl methylcellulose was used as matrixing agent, M.C.C., and Na2Co3 were used. The manufactured tablets assessed for physicochemical parameters such as weight variety, hardness, friability, floating properties (total floating time and floating lag time), in vitro drug release, and drug content, and stability study. The drug- polymer interaction was studied by differential scanning calorimetry and Fourier transform infrared (FTIR). On the basis of preliminary batches, the PF3 batch giving more drug release so that the PF3 batch is used for DoE process. Formulation F7 had been selected as an optimum formulation as it displayed more comparison in dissolution profile with theoretical profile which is 99.89 ± 0.49%. The dissolution of batch F7 can be described by zero order kinetics (R2 = 0.954), First order- R2 = 0.87, Higuchi R2 = 0.989, and Peppa’s R2 = 0.99. Also studied X-ray Photographic Studies in Rabbits and showed tablet was float more than 8 h in gastric region of the Albino rabbits. It could be concluded from this study that the prepared Gastro-retentive tablet could reduce the frequency of dosage, dose related side effects, and increase the bioavailability.

Digestion of curcumin-fortified yogurt in short/long gastric residence times using a near-real dynamic in vitro human stomach

A dynamic in vitro human stomach (DIVHS), simulating the anatomical structures, peristalsis, and biochemical environments of a real stomach as practically as possible, was applied to mimic the gastric pH and emptying during yogurt digestion in short/long gastric residence times. The influences of peristalsis, dilution, and proteolysis on digesta viscosity were quantified respectively, indicating the dominant role of proteolysis and dilution. After incorporating curcumin-whey protein microparticles with targeted-release formula in yogurt, the peak curcumin release during intestinal digestion reached 43% at 120 min in the short gastric residence time and 16% at 180 min in the long gastric residence time. The change in the maximum curcumin release depended on the gastric emptying kinetics in each residence time. This emptying-kinetics dependence was reflected by the slower microparticle disintegration and proteolysis in the long gastric residence time. The dynamic reproduction of realistic gastric conditions using DIVHS helps revealing controlled release from foods.

Preparation of Acyclovir-Containing Solid Foam by Ultrasonic Batch Technology.

In recent years, the application of solid foams has become widespread. Solid foams are not only used in the aerospace field but also in everyday life. Although foams are promising dosage forms in the pharmaceutical industry, their usage is not prevalent due to decreased stability of the solid foam structure. These special dosage forms can result in increased bioavailability of drugs. Low-density floating formulations can also increase the gastric residence time of drugs; therefore, drug release will be sustained. Our aim was to produce a stable floating formula by foaming. Matrix components, PEG 4000 and stearic acid type 50, were selected with the criteria of low gastric irritation, a melting range below 70 °C, and well-known use in oral drug formulations. This matrix was melted at 54 °C in order to produce a dispersion of active substance and was foamed by different gases at atmospheric pressure using an ultrasonic homogenizer. The density of the molded solid foam was studied by the pycnometer method, and its structure was investigated by SEM and micro-CT. The prolonged drug release and mucoadhesive properties were proved in a pH 1.2 buffer. According to our experiments, a stable foam could be produced by rapid homogenization (less than 1 min) without any surfactant material.

PH-dependent vs. constant release of mesalazine in the treatment of ulcerative colitis: Do drug delivery concepts determine therapeutic efficacy? (Review).

Inflammatory bowel diseases (IBD) have developed to become a major global health problem. Ulcerative colitis (UC) is one of two main types of IBD, and >90% of patients suffering from mild or moderate forms of UC are treated with mesalazine, a well-tolerated and cost-effective drug. To allow oral administration, the drug has to be protected from resorption before it can reach the affected sites in the colon. The drug is therefore released from most currently used medications either constantly slow (time-dependent) or triggered by an increased pH during gastrointestinal transition. Both variants are widely used in clinical practice and it is surprising that they have not yet been compared directly in a large clinical study. In this overview, the evidence that may suggest preferential use of one type of mesalazine formulation over the other in general or for defined subgroups of patients is summarized and evaluated. Data from in vitro modelling of drug release and measurements of drug concentrations in colonic mucosa suggest that in many cases, constant release and pH-dependent formulations are of similar therapeutic efficiency; however, pH-triggered release may be superior in patients with proctitis-type UC or sites of inflammation in the proximal colon. Additionally, patients with a long gastric residence time, slow small intestinal transition, disease-related diarrhea or sensitivity to systemic adverse effects may benefit more from pH-dependent release formulations. In general, medications based on both concepts show similar efficacies, but the pH-dependent release formulations seem to be more robust in the treatment of a not further classified group of patients with UC. Future comparative clinical studies are required to clearly define the subgroups of patients that should be treated preferably with constant or pH-dependent release formulations of mesalazine.

Hydrodynamically Balanced Capsule of Famotidine: An Improved Delivery via Gastroretentive Hydrogels

Objective: The aim of the present study was to increase the absolute bioavailability of famotidine, enhanced patient compliance in the treatment of peptic ulcer by increasing its gastric residence time and controlled local release of drug upto 12 hours. Materials and Methods: Hydrodynamically balanced capsules of famotidine were prepared, consisting of floating matrix granules, which formed hydrogels. Effects of different formulation variables namely hypromellose (HPMC 4000 cps, HPMC 5600 cps, HPMC 15000 cps), effervescent agent (potassium bicarbonate) and mixing time were studied. Optimization study included 23 full factorial design with t50% and t80% as the kinetic parameters (response variable). Matrix characterization included scanning electron microscopy. All prepared formulations were evaluated to various parameters such as micromeritics properties, % buoyancy and in vitro drug release studies. Results and Discussion: The optimized formulation (F4) remains buoyant for more than 12 hrs. The in-vitro drug release study indicated that increasing the viscosity of HPMC resulted in sustained drug release with long floating duration. SEM studies showed definite entrapment of the drug in the matrix and hydrogel formation. Results showed a pH independent but polymer viscosity dependent drug release profile. The release kinetics followed Higuchi model and mechanism of release was found to be non-Fickian diffusion. Conclusion: Famotidine-loaded hydrodynamically balanced capsules were successfully prepared and prove to be useful for prolonged gastric residence of the drug, better bioavailability, patient compliance and improve delivery for enhanced anti-ulcer activity.

Effect of gastric residence time on the oral absorption of rebamipide sustained-release tablets in beagle dogs

Effect of gastric residence time on the oral absorption of rebamipide sustained-release tablets in beagle dogs

FORMULATION AND EVALUATION OF FLOATING IN SITU GEL OF OMEPRAZOLE MAGNESIUM FOR ORAL DRUG DELIVERY SYSTEM

Objective: Omeprazole magnesium is indicated for the treatment of erosive esophagitis associated with gastroesophageal reflux disease. It is one of the highly prescribed proton pump inhibitor in the management of peptic ulcer diseases. The therapeutic concentration of a drug in blood can be maintained for a prolonged period of time by administering it in the form of in situ floating gel dosage form. Omeprazole magnesium undergoes degradation at a low pH of the esophagus and stomach; it is therefore given as in situ gel, so, there is minimum contact with acidic pH. Methods: Omeprazole magnesium suspension prepared using various polymers and floating agents in varying concentrations. Several evaluation tests including dissolution test to ensure the release of the drug from formulation by in vitro technique, color and homogeneity, in vitro floating duration, in vitro gelling capacity, drug content determination, pH of the formulation, and floating lag time were studied. Results: All formulations demonstrated good Fourier-transform infrared compliance and no interaction between drug, polymer, and other excipients. The study’s findings show that the formulation F6 showed the best results. Conclusion: The developed formulation was a viable alternative conventional solution by virtue of its ability to enhance bioavailability through its longer gastric residence time and ability to sustain drug release as well as the advantage of floating and pH which minimize the degradation of omeprazole magnesium which is easily degraded by acidic environment.

Development of a furosemide-containing expandable system for gastric retention

More than 50 years ago, the first gastroretentive dosage forms came up. Since then, no practical and at the same time reliable gastroretentive system is available on market. A major obstacle in the development of novel gastroretentive systems is the lack of proper predictive test methods. In the present work, we aimed at developing and fully characterizing an expandable gastroretentive system containing furosemide as model drug. On the one hand, we used well-established in vitro tests for drug dissolution and gastroretentive properties (paddle apparatus, swelling characteristics). On the other hand, we used two novel models (dissolution stress test device, mechanical antrum model) to assess these properties under biorelevant conditions. Moreover, we performed an in vivo study under fed and fasted conditions that combined blood sampling and a high-resolution imaging technique (magnetic marker monitoring) to determine gastrointestinal location with the assessment of a pharmacodynamic endpoint (urinary sodium excretion). In vitro dissolution tests confirmed prolonged drug release over more than 8 h independent from pH and with slight pressure sensitivity. Swelling studies indicated good swelling behavior within 4 h along with medium gastroretentive properties as determined with the mechanical antrum model. In vivo imaging showed prolonged gastric residence time after fed compared to fasted administration (481 min vs 38 min). Comparison of geometric means of AUCo-tlast of the model drug confirmed this observation with 10 times higher value after fed administration. Urinary excretion of sodium well reflected the increased sodium-reuptake inhibition due to higher furosemide exposure under fed conditions.However, the poor performance after fasted intake of the system is in line with data from several other gastroretentive formulations. The present study highlighted the value of novel test methods during the development of gastroretentive formulations. Yet, a system with reproducible gastroretentive properties especially under fasted conditions has to be designed.

Evaluation of Metformin Hydrochloride Floating Drug Delivery System: In vitro Study and In vivo Prediction

Aim: This research work was aimed to evaluate Metformin hydrochloride (MH) floating dosage form by In vitro evaluation/In vivo prediction and to evaluate it’s predictability through it’s application during the R&D using Insilico technique in WINONLIN Software. MH was examined as a model drug, which is a biguanide and is an hypoglycemic agent administered orally. The study was aimed to determine the the systemic concentrations of MH using In-vivo prediction.
 Study Design: Fabrication and assessment of Metformin hydrochloride floating drug delivery system: In Vitro evaluation /In Vivo prediction. Biorelevant media was selected for dissolution profile of 12 units of dosage form. Software assisted program used for data feeding and results output.
 Methodology: The absorption window for MH is the upper portion of the small gut in which the GI absorption is complete after 6 h. Hence gastroretentive formulation was developed and validity of dissolution study was extended by In vivo pharmacokinetic prediction using WinNonlin Software. A mechanistic oral absorption model was built in Phoenix WinNonlin® software.
 In the presented work, significant yet crucial, gastrointestinal (GI) variables are considered for biopredictive dissolution testing to account for a valuable input for physiologically-based pharmacokinetic (PBPK) platform programs. While simulations are performed and mechanistic insights are gained from such simulations from the WinNonlin program.
 Results: These floating tablets were observed for In vitro release and studied for In vivo pharmacokinetic prediction. From the obtained values, a meaningful In vivo prediction was done. interestingly from the results attained floating tablets showed sustained drug release and extended drug absorbed in 24h. Fascinatingly, from the data it was proved that drug formulation resides for desired time. The absorption of MH from the developed CR tablet was 1.4 fold higher than its marketed tablet and it had higher AUC0–t values than the marketed product which indicates superior bioavailability of test product compared to marketed tablet with similar dose in Invivo pharmacokinetic prediction. The mean value of biological half-life (t1/2) and Tmax of MH from test formulation is two times more, Test product has shown higher MRT, showing that the drug is maintained longer in the body in comparison to marketed product indicates controlled absorption.
 Conclusion: Here we concluded that, a comparative prediction pharmacokinetic evaluation of the fabricated controlled release tablets and the marketed formulation indicates that the fabricated controlled release tablets are well absorbed and the degree of absorption is greater than that of the marketed ER formulation with larger gastric residence time.

Mechanical strength and gastric residence time of expandable fibrous dosage forms

Expandable, gastroretentive dosage forms are promising for precise control of drug concentration in blood. So far, however, short gastric residence times and safety considerations have limited their use. To mitigate such limitations, in this work expandable fibrous dosage forms were investigated for mechanical strength and gastric residence time in dogs. The fiber formulation comprised ibuprofen drug; water-absorbing, high-molecular-weight hydroxypropyl methylcellulose (HPMC) excipient; fiber-strengthening, enteric methacrylic acid-ethyl acrylate excipient; and barium sulfate, a gastrointestinal contrast agent. The fibers were coated either with a hydrophilic sugar, or with a strengthening enteric excipient. Upon administration to a dog, in the stomach the dosage form with sugar-coated fibers expanded to 1.7 times its initial radius in 50–100 minutes, and disintegrated after 4.8 hours. The dosage form with the enteric-excipient-coated fibers, by contrast, expanded to 1.6 times the initial radius in 5 hours, and fractured after 31 hours due to cyclic loads applied by the contracting stomach walls. The fragments passed into the small intestine where they dissolved in less than 2–3 hours. Diametral compression tests and dynamic fatigue failure models show that the substantial increase in gastric residence time is due to strengthening of the fibers by the enteric-excipient coating. Because the enteric excipient is a rubbery semi-solid in the acidic gastric fluid and dissolves in the pH-neutral intestinal fluids, safety concerns should be minimal. Thus, expandable fibrous dosage forms can be readily designed for prolonged, safe gastric retention.

A Review on Floating Multi-particulate Drug Delivery System

The objective of writing this review on Floating Drug Delivery Systems (FDDS) was to accumulate new work with a special focus on the primary floatation mechanism for gastric retention. Drug delivery systems are those that instantly float on contact with gastric fluids and present promising approaches to improve the bioavailability of drugs with absorption windows in the stomach or upper small intestine, imbalanced in the intestinal or colonic environment, and exhibit low solubility at high pH standards. It is a novel drug delivery system that takes full advantage of effectiveness and compliance. Physical problems such as short gastric residence time and unpredictable gastric emptying time were overcome with the use of floating dosage forms that provide the possibility of local and systemic effects. The floating drug delivery system allows prolonged and continuous entry of the drug into the upper part of the gastric retention pathway and increases the bioavailability of the medication characterized by a narrow absorption window. This review provides detailed information on the pharmaceutical basis of its Introduction, Advantages, Disadvantages, Factors Affecting Gastric Emptying, and Criteria for Suitable Drug Products for Floating Gastric-Retention, Classification of Floating Multiparticulate Drug Delivery System, and Characterization of Floating Multiparticulate Drug Delivery System. These systems are beneficial for various difficulties encountered during the development of a pharmaceutical dosage form and the future potential of FDDS. This review article has attempted to announce to readers about the floating drug delivery system.